HELSINKI, Finland, April 14, 2010 /PRNewswire/ -- Atacama Labs Oy today announced the appointment of Dr. Robert Lammens as Chief Technology Officer, CTO.
Dr. Lammens is responsible for the further development of the company's proprietary Pneumatic Dry Granulation technology, PDG Technology(TM). Dr Lammens also develops the company's own product portfolio and supports clients in developing pharmaceutical products with the PDG Technology(TM).
"The appointment of Dr. Lammens strengthens our scientific and technical capabilities significantly. The combination of his knowledge and our unique PDG Technology(TM) is an enormous opportunity for Atacama and our customers. Dr Lammens' proven track record in development of pharmaceutical processes will raise Atacama to the next level," said Mr. Jari Ovaskainen, Chairman of the Board of Directors, Atacama Labs Oy.
Dr. Robert Lammens is an experienced and acknowledged expert in the Pharmaceutical Technology, especially in dry granulation. He has received his Ph.D. in the field of Pharmaceutical Technology from the University of Leiden (the Netherlands) in 1981. After that he joined Bayer AG in Leverkusen, where he worked for 23 years mainly in the field of solid dosage forms. In addition to his new position as the CTO of Atacama Labs, he will continue as Senior Lecturer at the Department of Pharmaceutical Technology of University of Bonn, where he is coaching several Ph.D. projects in the field of granulation and tableting in close cooperation with the director of this department, Prof. Dr. Klaus-Jurgen Steffens. He is also an adviser to Gerteis Maschinen + Processengineering AG, the leading compactor vendor in the world technology-wise.
About Atacama Labs Oy
Atacama Labs Oy is a privately owned specialty pharmaceutical company that offers:
CONTACT: Steffen Mittwich, CEO, Atacama Labs Oy, tel. +41-79-369-3410